Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart

Diabetes

Volumn 58, Issue 11, 2009, Pages 2536-2546

  Hwi, Jin Ko ^a,b   Zhang, Zhiyou ^b   Dae, Young Jung ^a,b   Jun, John Y ^b   Ma, Zhexi ^b   Jones, Kelly E ^b   Chan, Sook Y ^b   Kim, Jason K ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ARTICLE; CARDITIS; CONTROLLED STUDY; DIET; GLUCOSE METABOLISM; HEART FAILURE; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; NUTRIENT; OBESITY; PRIORITY JOURNAL;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DIABETIC ANGIOPATHIES; DIETARY FATS; FATTY ACIDS, NONESTERIFIED; GLUCOSE; HEART; HEART FAILURE; HUMANS; INFLAMMATION; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM;

EID: 70350560556     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-1361     Document Type: Article

References (46)

1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-1146
2. Rodrigues B, McNeill JH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovascular Res 1992;26:913-922
3. Taegtmeyer H, Passmore JM. Defective energy metabolism of the heart in diabetes. Lancet 1985;1:139-141
4. Kolter T, Uphues I, Eckel J. Molecular analysis of insulin resistance in isolated ventricular cardiomyocytes of obese Zucker rats. Am J Physiol 1997;273:E59-E67
5. Ohtake T, Yokoyama I, Watanabe Y, Momose T, Serezawa T, Nishikawa J, Sasaki Y. Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET. J Nucl Med 1995;36:456-463
6. Lopaschuk GD. Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrates/lipid metabolism. Coronary Artery Dis 1996;7:116-123
7. Park S-Y, Cho Y-R, Kim H-J, Higashimori T, Danton C, Lee M-K, Dey A, Rothermel B, Kim Y-B, Kalinowski A, Russell KS, Kim JK. Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes 2005;54:3530-3540 (Pubitemid 43334346)
8. Chen H. Cellular inflammatory responses: novel insights for obesity and insulin resistance. Pharmacological Res 2006;53:469-477 (Pubitemid 43767552)
9. Wellen KF, Hotamisligil GS. Inflammation, stress, diabetes. J Clin Invest 2005;115:1111-1119
10. Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, Ranganathan G, Peterson CA, McGehee RE, Kern PA. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues. Diabetes 2005;54:2305-2313
11. Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol 2007;292:E166-E174
12. Permana PA, Menge C, Reaven PD. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Comm 2006;341:507-514
13. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830 (Pubitemid 38063705)
14. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91 (Pubitemid 23036092)
15. Steinberg GR, Michell BJ, van Denderen BJW, Watt MJ, Carey AL, Fam BC, Andrikopoulos S, Proietto J, Gorgun CZ, Carling D, Hotamisligil GS, Febbraio MA, Kay TW, Kemp BE. Tumor necrosis factor α-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 2006;4:465-474 (Pubitemid 44834113)
16. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol 2001;280:E745-E751 (Pubitemid 33774944)
17. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002;51:3391-3399 (Pubitemid 35403441)
18. Shi H, Tzameli I, Bjorbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 2004;279:34733-34740 (Pubitemid 39318104)
19. Pedersen BK, Febbraio MA, Mooney RA. Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007;102:814-816
20. Park S-Y, Cho Y-R, Finck BN, Kim H-J, Higashimori T, Hong E-G, Lee M-K, Danton C, Deshmukh S, Cline GW, Wu JJ, Bennett AM, Rothermel B, Kalinowski A, Russell KS, Kim Y-B, Kelly DP, Kim JK. Cardiac-specific overexpression of PPARα causes insulin resistance in heart and liver. Diabetes 2005;54:2514-2524
21. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK. Differential effects of interleukin-6 and 10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004;53:1060-1067 (Pubitemid 38436619)
22. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997;34:25-33 (Pubitemid 27261909)
23. Young LH, Li J, Baron SJ, Russell RR. AMP-activated protein kinase: a key stress signaling pathway in the heart. Trends Cardiovasc Med 2005;15:110-118
24. Shi H, KoKoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-3025 (Pubitemid 44684486)
25. Kim JK. Fat uses a TOLL-road to connect inflammation and diabetes. Cell Metab 2006;4:417-418
26. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003;52:2784-2789
27. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002;32:14-23
28. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451
29. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312 (Pubitemid 32151228)
30. Stratford S, Hoehn KL, Liu F, Summers SA. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 2004;279:36608-36615 (Pubitemid 39129005)
31. Kurihara T, Bravo R. Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC. J Biol Chem 1996;271:11603-11607 (Pubitemid 26161808)
32. Weisberg SP, Hunter D, Humber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AW Jr. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006;116:115-124 (Pubitemid 43121796)
33. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumor necrosis factor α and blood cytokine production in type 2 diabetes. Life Sci 2000;67:291-300 (Pubitemid 30413937)
34. Kanda H, Tateya S, Tamori Y, Kokota K, Hiasa K-I, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macropahge infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494-1505
35. Takahashi K, Mizuarai S, Araki H, Mashiko S, Ishihara A, Kanatani A, Itadani H, Kotani H. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 2003;278:46654-46660
36. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, Young LH. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008;451:578-583
37. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson J-O. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8:75-79 (Pubitemid 34101732)
38. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol 2004;287:E182-E187
39. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 2006;55:2688-2697 (Pubitemid 44923666)
40. Geiger PC, Hancock C, Wright DC, Han D-H, Holloszy JO. IL-6 increases muscle insulin sensitivity only at superphysiological levels. Am J Physiol 2007;292:E1842-E1846
41. Spangenburg EE, Brown DA, Johnson MS, Moore RL. Exercise increases SOCS-3 expression in rat skeletal muscle: potential relationship to IL-6 expression. J Physiol 2006;572:839-848
42. Febbraio MA, Pedersen BK. Muscle derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 2002;16:1335-1347
43. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-2556 (Pubitemid 30339210)
44. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000;275:15985-15991 (Pubitemid 30366903)
45. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002;277:42394-42398 (Pubitemid 35257562)
46. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine-signaling-3 (SCOS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003;278:13740-13746